ARTICLE | Clinical News
Acomplia rimonabant regulatory update
June 27, 2005 7:00 AM UTC
FDA accepted for filing an NDA for Acomplia rimonabant to manage cardiovascular risk factors. The PDUFA date is in the first quarter of 2006. An MAA for the cannabinoid CB1 receptor antagonist is als...